Conversion GemsConversion Gems
heartflow logo
Reviewed · Updated 2026-06-19

heartflow

AI-powered cardiac imaging platform for non-invasive heart disease detection.

Reviewed by the Conversion Gems editorial team ·
Try heartflow
Pricing
Free Trial
Best for
Cardiologists
Category
Developer & Technical
The bottom line

The gold-standard non-invasive coronary AI for institutions serious about reducing unnecessary invasive angiography.

7.7
Our score
7.7 / 10
Conversion Gems editorial verdict
Per-case (~$1,000/case); insurance reimbursed
Features9/10
9 - full non-invasive CAD suite (Roadmap, FFRCT, Plaque Analysis); FDA-cleared; 0.94 AUC; 90-min turnaround from CT to result.
Value7/10
7 - ~$1k/case is largely insurance-reimbursed, making it cost-neutral for most US institutions; limited value outside reimbursement markets.
Ease of use6/10
6 - institutional setup and CCTA integration is heavy; per-case workflow itself is streamlined once deployed.
Ecosystem8/10
8 - 1,800+ institutions, Category One CPT codes, ACC/AHA guideline endorsement, and availability across US, EU, UK, Japan, Canada.
Support8/10
8 - HeartFlow Support bundles clinical, operational, technical, and financial reimbursement resources for program development.
What it really is

HeartFlow — AI-powered cardiac FFR-CT analysis platform for non-invasive coronary artery disease diagnosis.

Our take

HeartFlow is a clinical-grade medical AI platform used by 1,800+ hospitals and health systems, not a developer tool — the DB category 'Developer & Technical' is incorrect; this belongs in Medical / Clinical AI. The DB price tier 'free_trial' is also wrong: HeartFlow uses enterprise per-case pricing (~$1,000/case, Medicare- and commercially-reimbursed) with no public free trial. Its HeartFlow ONE platform combines Roadmap Analysis, FFRCT Analysis, and Plaque Analysis to deliver a complete non-invasive CAD diagnostic workflow from a single CT scan.

Why we rate it

HeartFlow is FDA-cleared, ACC/AHA Chest Pain Guideline-endorsed, and backed by large multi-center trial data showing 69% reduction in unnecessary invasive coronary angiographies. The platform is operationally proven at 1,800+ institutions globally, with a $176M revenue run-rate in 2025.

The catch

Enterprise-only procurement — no self-serve onboarding, no public pricing, and meaningful institutional setup overhead. Limited to markets with CCTA infrastructure and insurer reimbursement pathways (primarily US, EU, UK, Japan, Canada).

Best for
Hospitals and health systems running high-volume CCTA programs
Interventional cardiologists needing non-invasive lesion-specific physiology before revascularization decisions
Cardiac imaging centers seeking ACC/AHA guideline-aligned workflows
Not good for
Small or independent cardiology practices without CT infrastructure
Markets lacking established CCTA reimbursement pathways
Use cases outside coronary artery disease (no general radiology or non-cardiac AI)
Friction report
Time to value
Slow: institutional procurement, credentialing, and CCTA workflow integration required before first case analysis. Once live, per-case turnaround is ~90 minutes.
Scale breakpoint
Per-case billing scales linearly; high-volume programs benefit from enterprise contract negotiation but costs grow directly with caseload.
Walled garden
High: analyses are performed on HeartFlow's proprietary cloud infrastructure using CT scan uploads; results are delivered back to the institution but the computational engine is fully opaque and vendor-locked.

A look inside

heartflow product screenshot

Frequently Asked Questions

Alternatives

Step up

Invasive FFR catheterization (Philips Volcano or Abbott pressure-wire systems) for highest-acuity cases requiring definitive physiologic measurement.

Lighter alternative

Cleerly CCTA plaque analysis for institutions needing AI-assisted reading without full FFRCT workflow.

Ready to try heartflow?
Opens the official site — we may earn a commission if you sign up.
Try heartflow

Tags

#Healthcare#Cardiology

Explore related categories

Conversion Gems independently reviews every tool. We may earn a commission if you sign up through our links — it never affects our verdict or ranking.